论文部分内容阅读
目的检测肺腺癌患者血清中血管内皮生长因子(VEGF)的表达变化,分析其临床意义,为肺腺癌病情判定及预后估计提供辅助手段。方法采用酶联免疫吸附反应(enzyme-linkedimmunosorbant assay,ELLSA)法检测60例肺腺癌患者,20例健康人和20例肺良性病变血清中VEGF含量,并分析其临床意义。结果正常健康人与肺良性病变患者血清中VEGF含量差异无统计学意义(P>0.05);肺腺癌患者血清VEGF含量较健康人明显升高(P<0.01),且随着肺腺癌的分期、分级和淋巴结转移而显著增高(P<0.01),且与血清VEGF含量呈正相关(P<0.01)。结论肺腺癌患者血清中VEGF表达的增高与肿瘤的发生、发展及恶性行为有关,可作为临床上判断预后的指标之一。
Objective To detect the expression of vascular endothelial growth factor (VEGF) in the serum of patients with lung adenocarcinoma, and to analyze the clinical significance of the expression of VEGF in the lung adenocarcinoma. Methods The serum levels of VEGF in 60 patients with lung adenocarcinoma, 20 healthy people and 20 patients with benign lung diseases were detected by enzyme-linked immunosorbant assay (ELLSA), and their clinical significance was analyzed. Results There was no significant difference in serum VEGF levels between normal and benign pulmonary lesions (P> 0.05). Serum VEGF levels in patients with lung adenocarcinoma were significantly higher than those in healthy controls (P <0.01) Staging, grading and lymph node metastasis (P <0.01), and was positively correlated with serum VEGF (P <0.01). Conclusion The increased expression of VEGF in the serum of patients with lung adenocarcinoma is related to the occurrence, development and malignant behavior of the tumor, and may be used as one of the indicators to judge the prognosis of the patients.